Gilead Sciences participates in CIIE for first time, brings new products

"To further help address the health challenges faced by the people and communities, we need more than just drugs," said Jim Jin, vice-president of the company and general manager of its China arm.

"Therefore, we won't stop at science, but instead hold out hope that our innovative products can benefit more patients through continuous efforts in removing the barriers in the medical service process."

Gilead plans to sign a strategic cooperation memorandum with Hainan Lecheng during the expo, jointly promoting the implementation of more innovative products and diagnostic and treatment programs urgently needed in the clinical field in Lecheng pilot area.

Gilead is an innovation-driven company deeply rooted in scientific research and development. With its commitment to breaking through impossibilities, it has been pursuing new therapies, and solving the problems of disease treatment.

As part of its efforts to improve R&D capability in China, the company is planning to recruit more talent and include more Chinese patients in its global clinical trials.

In response to the national action plan for the prevention and control of viral hepatitis, Gilead will sign a three-year strategic cooperation project to support the national action plan and eliminate the public health hazards of hepatitis C. It will do so with the Chinese Association of STD and AIDS Prevention and Control during the expo.

"Whether it is about the introduction of innovative products or the expansion of product lineup, every expansion of Gilead in China will adhere to its original intention and commitment of patient-centered action," Jin said.

"With the willingness to cultivate China with in-depth effort, we very much hope to accelerate the introduction of innovative products through the platform of the CIIE, to provide more and better innovative products for Chinese patients," Jin added.